BridgeBio Q2 boosted by Attruby growth, advances 3 NDAs and secures $1B launch funding

 

BridgeBio Q2 boosted by Attruby growth as company advances three NDAs and secures $1B launch funding

• Q2 2026 revenue $243.7M (+120% YoY) beat estimates, while EPS loss of $0.78 missed expectations.
• Attruby net revenue rose to $222.4M, driving total Q2 revenue to $243.7M.
• Attruby is fastest-growing brand in ATTR-CM, with 23% sequential growth and rising first-line share.
• New kidney-protection data and multiple real-world studies further differentiate Attruby versus tafamidis clinically.
• Cardio Transform combo failure reinforces stabilizers as first-line backbone, favoring Attruby’s near-complete stabilizer profile.
• Three late-stage programs (LGMD2I, ADH1, achondroplasia) are now with regulators, all showing strong Phase III data.
• BBP-418 (LGMD2I) has FDA priority review; PDUFA November 27, 2026, no advisory committee planned.
• Encaleret for ADH1 granted FDA priority review; PDUFA May 8, 2027; MAA under EMA review.
• Infigratinib NDA for achondroplasia submitted, with expected U.S. approval around mid-2027 and EU filing in Q4 2026.
• Operating loss improved ~20% YoY to $107.1M despite heavy launch investments, showing emerging operating leverage.
• $1B preferred equity raise lifts pro forma cash to ~$1.7B, funding Attruby growth and three upcoming launches.
• Main concern: execution and pricing/access dynamics amid intensifying ATTR-CM competition and three near-simultaneous rare disease launches.
• Strong quarter, driven by accelerating Attruby adoption, expanding clinical differentiation, and de-risked late-stage rare disease pipeline.

https://finviz.com/stock?t=BBIO&p=d